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Summary
Objective: Serotypeable strains of Haemophilus influenzae, which can cause invasive infections,
are found in the respiratory tract at low frequencies. We compared the antibiotic resistance of
the typeable and nontypeable strains of H. influenzae in respiratory tract specimens obtained in
Japan.
Methods: We determined the serotypes and the antibiotic susceptibilities of 440 clinical H.
influenzae strains isolated from respiratory tract specimens. We also examined the prevalence
of genotypes that are associated with b-lactam resistance.
Results: The majority of the strains were nontypeable (421 strains, 95.7%). The remainder
belonged to serotypes b (10 strains, 2.3%), e (three strains, 0.7%), or f (six strains, 1.4%). The
type b strains exhibited the expression of b-lactamase and resistance mutations in penicillin-
binding protein 3 with significantly higher frequencies than other strains.
Conclusions: H. influenzae type b strains, which are associated with meningitis and bacteremia,
derived from respiratory tract specimens, shared more b-lactam-resistant mechanisms than
nontypeable and other serotype strains.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Along with Streptococcus pneumoniae, Haemophilus influ-
enzae is a major causative factor of respiratory and otolar-
yngology infections, especially community-acquired
pneumonia in elderly persons and otitis media and sinusitis* Corresponding author. Tel.: +81 11 611 2111; fax: +81 612 5861.
E-mail address: fujii@sapmed.ac.jp (N. Fujii).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.09.017in children.1,2 Penicillins and second- or third-generation
cephalosporins (CEPs) are used as the first-choice antibiotics
for these infectious diseases. There has been a recent world-
wide increase in infections with two types of b-lactam-
resistant H. influenzae strains. One is due to the expression
of b-lactamases, and another is mutations in penicillin-bind-
ing proteins (PBPs), especially PBP3.3,4 With regard to the b-
lactamase-carrying H. influenzae strains, two types of b-
lactamases denoted as TEM-1 and ROB-1 have been observed.
TEM-1 is highly dominant in Japan compared to ROB-1.5 WithPublished by Elsevier Ltd. All rights reserved.
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b-lactamases — these are called b-lactamase-negative ampi-
cillin-resistant (BLNAR) strains — there has been a recent and
highly problematic increase in community-acquired infec-
tions with these strains.4,6 BLNAR strains are highly prevalent
in Japan.
Most H. influenzae clinical isolates from respiratory tract
infections do not carry capsular polysaccharides and are thus
nontypeable. However, the typeable strains, which are less
prevalent, are associated with invasive infectious diseases
such as meningitis and bacteremia. This is because they bear
capsular polysaccharides that facilitate their escape from
complement-mediated killing and phagocytosis.7 Of the
typeable strains, type b strains occur most frequently and
are responsible for more than half of all cases of pediatric
bacterial meningitis in Japan.8 H. influenzae type b (Hib)
vaccine was introduced in Japan in 2007, so most children
have never been vaccinated.
Our ability to treat invasive H. influenzae infections with
antibiotics will be threatened by the increasing prevalence of
antibiotic-resistant typeable H. influenzae strains. This study
was undertaken in order to determine the extent of this
problem; we examined susceptibility to various antibiotics
and the b-lactam resistance genotypes of clinical H. influ-
enzae isolates obtained from respiratory tract specimens
provided by clinical laboratories of general hospitals and a
commercial clinical laboratory in Japan.
Materials and methods
Bacterial strains
Between 2002 and 2004, 440 H. influenzae clinical strains
were isolated from respiratory tract specimens obtained in
hospitals in the Hokkaido Prefecture, Japan. The strains were
collected and stocked by Sapporo Clinical Laboratory, Inc.
(Sapporo, Japan), Muroran General Hospital (Muroran,
Japan), and Hokkaido University Hospital (Sapporo, Japan).
This study was approved by the respective review boards of
the institutions and the corporation. Sapporo Clinical Labora-
tory, Inc. serves almost the entire area of the Hokkaido
Prefecture. Due to the Act on the Protection of Personal
Information in Japanese law, we were only given the follow-
ing information: patient age and sex, the clinical source, and
the name of the city in which the strains were isolated. The
isolates obtained from the respiratory specimens (sputa,
rhinorrhea, pharyngeal fluids, nasal cavity, otopyorrhea,
and bronchial lavage fluids) were examined in this study.
The strains were identified as H. influenzaewith WalkAway40
(Dade Behring, Tokyo, Japan). We also tested X and Y growth
requirements by a disk method (Eiken Chemical, Tokyo,
Japan). All isolates were grown at 37 8C in an atmosphere
of 5% CO2 on a chocolate agar II plate (Nippon Becton-
Dickinson, Tokyo, Japan).
Analysis of genotypes contributing to b-lactam
resistance
Genomic DNA isolated from the cells grown on chocolate
agar served as the template for PCR analysis that was
performed according to Hasegawa et al.9 PCR amplificationwas performed by using HotStarTaq DNA polymerase (Qiagen,
Hilden, Germany). The PCR detected the following genes:
outer membrane protein P6 (as a positive control for H.
influenzae), TEM-1 b-lactamase, and ROB-1 b-lactamase.
The genotypes of b-lactamase-negative ampicillin low resis-
tant (gLow-BLNAR) and b-lactamase-positive amoxicillin/
clavulanic acid low resistant (gLow-BLPACR) strains that bear
mutations in PBP3 that confer low-level b-lactam resistance
were detected by identifying the Asn526Lys amino acid sub-
stitution. The genotypes of b-lactamase-negative ampicillin
high resistant (gHigh-BLNAR) and b-lactamase-positive
amoxicillin/clavulanic acid high resistant (gHigh-BLPACR)
strains that bear mutations in PBP3 that confer high-level
b-lactam resistance were detected by identifying the
Ser385Thr and Asn526Lys amino acid substitutions. The
strains that did not contain the PBP3 resistance mutations
were genotypes b-lactamase-negative ampicillin susceptible
(gBLNAS) and b-lactamase-positive amoxicillin/clavulanic
acid susceptible (gBLPACS).
Serotype determination
Serotype was determined by the slide agglutination assay
using specific antisera (Denka Seiken, Tokyo, Japan) and by
PCR performed according to the method of Falla et al.10
b-Lactamase assay (disk method)
Strains were tested for b-lactamase production by using
nitrocefin-impregnated disks (Becton Dickinson, Cockeys-
ville, MD, USA).
Antibiotic susceptibility
Determination of the minimum inhibitory concentration
(MIC) of antibiotics according to the guidelines of the Clinical
and Laboratory Standards Institute (CLSI, Wayne, PA, USA)11
was performed as described previously.12
Statistical analysis
The data were statistically analyzed using the Fisher’s exact
test.
Results
A total of 440 H. influenzae strains were isolated from
respiratory tract specimens obtained between 2002 and
2004 from patients in the Hokkaido Prefecture, Japan. Of
these strains, 421 were nontypeable (95.7%), and 10 (2.3%),
three (0.7%), and six (1.4%) belonged to serotypes b, e, and f,
respectively. The patients were mainly pediatric (64.5%) and
the elderly (21.6%). The distribution of patient age was not
significantly different among serotypes (Table 1). Further-
more, the serotype distribution did not differ significantly in
terms of clinical source (Table 2) and city from which the
strains were isolated (data not shown). The expression of b-
lactamase by the 440 strains was determined by PCR and the
disk method. The results obtained from both methods were
consistent (data not shown). All b-lactamases detected were
Table 1 Relationship between patient age and Haemophilus influenzae serotype.
Age (years) Number of strains
Nontypeable b e f Total
<16 270 (64.1%) 7 (70%) 2 (66.7%) 5 (83.3%) 284 (64.5%)
16—59 61 (14.5%) 0 0 0 61 (13.9%)
>59 90 (21.4%) 3 (30%) 1 (33.3%) 1 (16.7%) 95 (21.6%)
Total 421 (100%) 10 (100%) 3 (100%) 6 (100%) 440 (100%)
Percentage values in parenthesis are calculated for each serotype.
Table 2 Relationship between type of clinical specimen and
Haemophilus influenzae serotype.
Specimen Number of strains
Nontypeable b e f Total
Sputum 183 5 2 0 190 (43.2%)
Rhinorrhea 170 3 1 0 174 (39.5%)
Pharyngeal fluid 32 0 0 1 33 (7.5%)
Nasal cavity 19 0 0 0 19 (4.3%)
Otopyorrhea 12 2 0 4 18 (4.1%)
Bronchial lavage
fluid
5 0 0 1 6 (1.4%)
Total 421 10 3 6 440 (100%)
586 S.Yokota et al.of the TEM-1 type. Although only 5.5% of the nontypeable
strains expressed b-lactamase, 50% of the type b strains
expressed it (Table 3). This difference was statistically sig-
nificant ( p < 0.01). b-Lactamase was not detected in any of
the serotype e or f strains.
With regard to the resistance mutations in PBP3 (Table 4),
10% of type b and 50.8% of nontypeable strains had PBP3
without resistance mutations (gBLNAS and gBLPACS strains).
This difference was statistically significant ( p < 0.05). The
PBP3 mutation that results in low-grade resistance (found in
gLow-BLNAR and gLow-BLPACR strains) was detected in 60%
of type b and 20.4% of nontypeable strains. This difference
was also statistically significant ( p < 0.01). The type b strains
did not differ from the nontypeable strains in terms of the
frequency of PBP3 mutations that lead to high-grade resis-
tance (found in gHigh-BLNAR and gHigh-BLPACR strains; 30%
vs. 28.7%). Thus, the low-level resistance mutation in PBP3
was more frequently found in the type b strains than the
nontypeable strains.
Table 5 shows the susceptibility of the H. influenzae
strains to ampicillin (ABPC). As expected from the data ofTable 3 Relationship between the expression of b-lactamase and
b-Lactamase Number of strains
Nontypeable b
Positive 23 (5.5%) 5a (50%)
Negative 398 (94.5%) 5 (50%)
Total 421 (100%) 10 (100%)
Percentage values in parenthesis are calculated for each serotype.
a p < 0.01 in the comparison of type b vs. nontypeable.genotypes described above, the type b strains were signifi-
cantly more frequently resistant to ABPC ( p < 0.01). In terms
of other antibiotics, all five b-lactamase-positive type b
strains were resistant to tetracycline (8 mg/ml), and one
of these strains was intermediate to chloramphenicol (4 mg/
ml). All type b strains were susceptible to clarithromycin
(MIC 4—8 mg/ml), levofloxacin (0.12 mg/ml), meropenem
(0.12 mg/ml), and rifampin (0.5 mg/ml). With regard to
nontypeable strains, eight (1.9%) tetracycline, three (0.2%)
chloramphenicol, eight (1.9%) levofloxacin, one (0.2%) mer-
openem, and no rifampin-resistant strains were observed. No
resistant strains of these antibiotics were observed in type e
or f strains.
Discussion
In the present study, we examined 440 H. influenzae clinical
isolates obtained from respiratory tract specimens from
Japanese patients. The vast majority (95.7%) of the strains
were nontypeable. The remainder belonged to serotypes b
(2.3%), f (0.7%), and e (1.4%). The prevalence of the ser-
otypeable strains observed here is comparable to those
estimated in other Japanese studies.13,14 We found that
50% of the serotype b strains expressed b-lactamase and
90% had some resistance mutations in PBP3, and that these
frequencies were significantly higher than those in the non-
typeable strains (5.5% and 49.1%, respectively) and the
strains with other serotypes (0% and approximately 33%,
respectively).
The typeable strains can cause invasive infections such as
meningitis and bacteremia because they evade complement-
dependent bacterial killing and phagocytosis by a function of
their capsular polysaccharide.7 In contrast, the nontypeable
strains, which do not bear capsular polysaccharides, are
rapidly killed in the blood in a complement-dependent man-
ner. The type b strains are still the most frequently isolated
of the six serotype strains in Japan, because H. influenzaeHaemophilus influenzae serotype.
e f Total
0 (0%) 0 (0%) 28 (6.4%)
3 (100%) 6 (100%) 412 (93.6%)
3 (100%) 6 (100%) 440 (100%)
Table 4 Relationship between penicillin-binding protein 3 (PBP3) genotypes and Haemophilus influenzae serotype.
Resistance mutations in PBP3 Number of strains
Nontypeable b e f Total
gBLNAS and gBLPACS 214 (50.8%) 1a (10%) 2 (66.7%) 4 (66.7%) 221 (50.2%)
gLow-BLNAR and gLow-BLPACR 86 (20.4%) 6b (60%) 0 (0%) 1 (16.7%) 93 (21.1%)
gHigh-BLNAR and gHigh-BLPACR 121 (28.7%) 3 (30%) 1 (33.3%) 1 (16.7%) 126 (28.6%)
Total 421 (100%) 10 (100%) 3 (100%) 6 (100%) 440 (100%)
gBLNAS, genotype of b-lactamase-negative ampicillin-susceptible; gBLPACS, genotype of b-lactamase-positive amoxicillin/clavulanic acid-
susceptible; gLow-BLNAR, genotype of b-lactamase-negative low-grade ampicillin-resistant; gLow-BLPACR, genotype of b-lactamase-positive
low-grade amoxicillin/clavulanic acid-resistant; gHigh-BLNAR, genotype of b-lactamase-negative high-grade ampicillin-resistant; gHigh-
BLPACR, genotype of b-lactamase-positive high-grade amoxicillin/clavulanic acid-resistant.
Percentage values in parenthesis are calculated for each serotype.
a p < 0.05 in the comparison of type b vs. nontypeable.
b p < 0.01 in the comparison of type b vs. nontypeable.
Table 5 Relationship between ampicillin (ABPC) susceptibility and Haemophilus influenzae serotype.
Susceptibility to ABPC Number of strains
Nontypeable b e f Total
Susceptible 291 (69.1%) 3 (30%) 2 (66.7%) 4 (66.7%) 300 (68.2%)
Intermediate 78 (18.5%) 1 (10%) 1 (33.3%) 2 (33.3%) 82 (18.6%)
Resistant 52 (12.4%) 6a (60%) 0 (0%) 0 (0%) 58 (13.2%)
Total 421 (100%) 10 (100%) 3 (100%) 6 (100%) 440 (100%)
Percentage values in parenthesis are calculated for each serotype.
a p < 0.01 in the comparison of type b vs. nontypeable.
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nationwide surveillance for bacterial meningitis in Japan
(2000—2004) reported that gBLNAR increased in recent years,
and approximately 70% H. influenzae strains shared resis-
tance mutations in PBP3.15,16 Approximately 20% type b
strains isolated from meningitis shared b-lactamase; how-
ever, b-lactamase-shared strains tended to decrease every
year in Japan (they decreased from about 25% in 2000—2002
to 15% in 2004).16 Nevertheless, the positive b-lactamase
rate of H. influenzae was higher in strains from meningitis
than in those from other diseases. The b-lactamase-positive
strains derived from respiratory diseases (mainly nontype-
able strains) had a prevalence of 15—20% until 1995, after
which the prevalence gradually declined to 3% in 1999.6 The
reason for this decrease is considered to be the predominant
use of oral third-generation CEPs, which are stable with
respect to b-lactamase.6
With regard to H. influenzae type b strains derived from
the respiratory tract, Nariai reported a prevalence of 56.7%
of BLNAR in type b strains and low frequency (6.7%) occur-
rence of b-lactamase derived from the nasopharynx of chil-
dren.17 In contrast, our study indicated that strains that were
derived from respiratory specimens shared b-lactamase with
a significantly higher rate (50%) compared to nontypeable
and other typeable strains. A similar observation was
reported by Luong et al.14 They reported that all three type
b strains tested expressed b-lactamase; however, the sample
numbers in that study were relatively low. Our present study
also showed thatmutations in PBP3 are found to have a higher
prevalence in low-grade resistance mutations, namely gLow-
BLNAR and gLow-BLPACR, in type b strains compared to otherstrains. The reason for the differences among these reports is
not yet clear. All b-lactamase-positive type b strains in the
present study also shared tetracycline resistance. So a resis-
tant type b clone or a plasmid carrying both b-lactamase and
tetracycline-resistant genes4 may spread. On the other hand,
the use of oral third-generation CEPs could cause a decrease
in b-lactamase-positive strains and an increase in BLNAR.
Further surveys on antibiotic usage are required to clarify
this. The increase in High-BLNAR inmeningitis is of concern.16
In conclusion, we observed a high frequency of resistance in
H. influenzae type b strains isolated from respiratory tract
specimens in a prefecture of Japan. It is feared that such
antibiotic-resistant type b strains, which can cause invasive
infections such as meningitis, are widespread.
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